Shanghai Clinical Cohort - Adrenal Disease

NCT07191951 | Recruiting

• 1 other identifier: SHDC2025CCS022
• Study Type: observational
• Target: 600
• Locations: 1 country
• Sites: 1

Brief Summary

As a vital organ responsible for producing life-sustaining hormones, the adrenal gland is associated with a wide range of diseases. These diseases affect multiple systems throughout the body and carry a high rate of mortality and disability. Current diagnosis and treatment face several challenges: significant variability in hormone testing results, inaccurate localization via imaging techniques, unclear molecular characteristics of adrenal tumors, and difficulty in determining prognosis through pathology. Therefore, establishing a clinical research cohort for adrenal diseases is essential. Such a cohort will enable in-depth exploration of disease mechanisms, identification of disease subtypes, optimization of diagnostic criteria, evaluation of treatment efficacy, advancement of personalized medicine, and formulation of prevention and treatment strategies.

Conditions

Adrenal Disease

Outcome Measures

Primary Outcomes (2)

• Post-Treatment Remission Rate

  at least six months or more

• Treatment Response Rate

  at least six months or more

Study Arms (1)

Adrenal cohort

Aged between 18 and 75 years; diagnosed with adrenal diseases, including primary aldosteronism, pheochromocytoma, Cushing's syndrome, congenital adrenal hyperplasia, adrenocortical carcinoma, etc.; in stable condition, capable of tolerating all examinations and follow-ups required by the study.

Other: Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.

Interventions

Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification. OTHER

Receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.

Adrenal cohort

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Aged between 18 and 75 years; diagnosed with adrenal diseases, including primary aldosteronism, pheochromocytoma, Cushing's syndrome, congenital adrenal hyperplasia, adrenocortical carcinoma, etc.; in stable condition, capable of tolerating all examinations and follow-ups required by the study. These patients receive adrenal surgery, radiotherapy, and/or medication therapy based on diagnosis and subtype classification.

You may qualify if:

• A signed and dated informed consent form
• Commitment to abide by the study procedures and cooperate with the implementation of the entire study process
• Patients diagnosed with adrenal diseases, including aldosteronism, Cushing's syndrome, pheochromocytoma, adrenocortical carcinoma, and congenital adrenal hyperplasia; regardless of whether they have received adrenal surgery, radiotherapy, and/or medication therapy
• Aged between 18 and 75 years

You may not qualify if:

• Subjects meeting any of the following criteria will be excluded from this study:
• Refuse to sign the informed consent form
• Patients without adrenal diseases

Sponsors & Collaborators

• Shanghai Jiao Tong University School of Medicine: lead
• Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine: collaborator
• RenJi Hospital: collaborator
• Shanghai Zhongshan Hospital: collaborator
• Shanghai Public Health Clinical Center: collaborator

Study Sites (1)

Jiang yiran

Shanghai, China

RECRUITING

MeSH Terms

Conditions

Adrenal Gland Diseases

Interventions

Radiotherapy

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Yiran Jiang

CONTACT

0086-021-64370045; jyr11662@rjh.com.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director of the Department of Endocrinology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Study Record Dates

• First Submitted: September 17, 2025
• First Posted: September 25, 2025
• Study Start: July 25, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: November 17, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)